Screener
10x Genomics, Inc. TXG Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $502,512 | $473,966 |
| Marketable securities | 49,521 | 49,443 |
| Accounts receivable, net | 47,545 | 47,013 |
| Other receivables | 3,084 | 35,480 |
| Inventory | 52,616 | 56,341 |
| Prepaid expenses and other current assets | 19,393 | 22,208 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s short-term investments?
- 10x Genomics, Inc. (TXG) reported short-term investments of $49.52M in Q2 2026.
- How has 10x Genomics, Inc.'s short-term investments changed year-over-year?
- 10x Genomics, Inc.'s short-term investments decreased by 0.1% year-over-year, from $49.55M to $49.52M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about 10x Genomics, Inc.'s short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude